Eris Lifesciences (BOM:540596) Cyclically Adjusted Revenue per Share: ₹135.49 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540596 Eris Lifesciences Ltd BOM:540596
95 GF Score
Price ₹1,399.95
GF Value ₹1,658.32
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eris Lifesciences Cyclically Adjusted Revenue per Share?

Eris Lifesciences BOM:540596 +0.08% 95 Cyclically Adjusted Revenue per Share is ₹135.49 as of Mar. 2026. GuruFocus rates BOM:540596 with a GF Score™ of 95/100 and a GF Value™ of ₹1,658.32 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Eris Lifesciences's adjusted revenue per share for the three months ended in Mar. 2026 was ₹54.951. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹135.49 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Eris Lifesciences's average Cyclically Adjusted Revenue Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-28), Eris Lifesciences's current stock price is ₹1399.95. Eris Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹135.49. Eris Lifesciences's Cyclically Adjusted PS Ratio of today is 10.33.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eris Lifesciences was 14.98. The lowest was 9.74. And the median was 12.01.


Eris Lifesciences  (BOM:540596) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eris Lifesciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1399.95/135.49
=10.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Eris Lifesciences was 14.98. The lowest was 9.74. And the median was 12.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Eris Lifesciences Cyclically Adjusted Revenue per Share Related Terms


Eris Lifesciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Eris Lifesciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eris Lifesciences Cyclically Adjusted Revenue per Share Chart

Eris Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 119.79 135.49

Eris Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.79 124.29 129.03 132.52 135.49

BOM:540596 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eris Lifesciences Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eris Lifesciences's Cyclically Adjusted PS Ratio falls into.


BOM:540596
95GF Score
Eris Lifesciences Ltd BOM:540596
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eris Lifesciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Eris Lifesciences's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=54.951/164.2724*164.2724
=54.951

Current CPI (Mar. 2026) = 164.2724.

Eris Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 13.323 105.961 20.655
201609 14.467 105.961 22.428
201612 13.408 105.196 20.938
201703 13.370 105.196 20.878
201706 13.465 107.109 20.651
201709 16.666 109.021 25.112
201712 15.103 109.404 22.677
201803 15.135 109.786 22.646
201806 17.928 111.317 26.457
201809 18.934 115.142 27.013
201812 18.077 115.142 25.790
201903 15.328 118.202 21.302
201906 19.766 120.880 26.861
201909 20.359 123.175 27.152
201912 19.012 126.235 24.741
202003 17.918 124.705 23.603
202006 21.197 127.000 27.418
202009 23.945 130.118 30.230
202012 22.434 130.889 28.156
202103 20.191 131.771 25.171
202106 25.293 134.084 30.988
202109 25.994 135.847 31.433
202112 24.126 138.161 28.686
202203 22.159 138.822 26.221
202206 28.810 142.347 33.247
202209 33.458 144.661 37.994
202212 30.725 145.763 34.627
202303 29.054 146.865 32.498
202306 33.801 150.280 36.948
202309 36.739 151.492 39.838
202312 35.482 152.924 38.115
202403 40.218 153.035 43.171
202406 52.396 155.789 55.249
202409 54.182 157.882 56.375
202412 53.017 158.323 55.009
202503 51.587 157.552 53.788
202506 56.498 159.755 58.096
202509 57.918 162.289 58.626
202512 58.790 163.281 59.147
202603 54.951 164.272 54.951

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹135.49 mean?
Eris Lifesciences (BOM:540596) has a Cyclically Adjusted Revenue per Share of ₹135.49 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Eris Lifesciences and its competitors.
Is Eris Lifesciences' Cyclically Adjusted Revenue per Share too high?
Eris Lifesciences' current Cyclically Adjusted Revenue per Share is ₹135.49. Overall, Eris Lifesciences has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Cyclically Adjusted Revenue per Share compare to ZTS?
Eris Lifesciences' Cyclically Adjusted Revenue per Share of ₹135.49 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Eris Lifesciences and its competitors. Eris Lifesciences's current Cyclically Adjusted Revenue per Share is ₹135.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (BOM:540596) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,658.32, compared to a current price of ₹1,399.95 — trading 15.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹135.49. Eris Lifesciences' overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Eris Lifesciences (BOM:540596), the current Cyclically Adjusted Revenue per Share is ₹135.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eris Lifesciences (BOM:540596) Overvalued in 2026?

Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued. The current stock price of ₹1,399.95 is trading 15.6% below its estimated GF Value™ of ₹1,658.32. GuruFocus considers Eris Lifesciences to be Modestly Undervalued.

Key valuation signals for BOM:540596:

  • Cyclically Adjusted Revenue per Share: ₹135.49
  • GF Value™: ₹1,658.32 vs. price of ₹1,399.95 (15.6% below fair value)
  • GF Score™: 95/100 with 6 warning signs

No single metric tells the full story. See the BOM:540596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eris Lifesciences Business Description

Other Exchanges ERIS:India
Address Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
95GF Score

Get the complete analysis for BOM:540596

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,399.95
Price
₹1,658.32
GF Value